Hangzhou Tigermed Consulting Co., Ltd
300347
Rang în acțiuni
#3218
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
Preț acțiune
$7.44
Capitalizare de piață
$5.49B
Schimbare (1 zi)
-2.99%
Schimbare (1 an)
-0.42%
Țară
CN
Tranzacționează Hangzhou Tigermed Consulting Co., Ltd (300347)
Categorie
Healthcare
Raport P/E pentru Hangzhou Tigermed Consulting Co., Ltd (300347)
Raport P/E la data de October 2026 TTM: 620.75
Conform celor mai recente rapoarte financiare și prețului acțiunilor Hangzhou Tigermed Consulting Co., Ltd, raportul P/E actual (TTM) este 620.75. La sfârșitul anului 2024, compania avea un P/E de 116.35.
Istoricul raportului P/E pentru Hangzhou Tigermed Consulting Co., Ltd din 2009 până în 2026
Raportul P/E la sfârșitul fiecărui an
| An | Raport P/E | Schimbă |
|---|---|---|
| 2026 (TTM) | 620.75 | 1,038.57% |
| 2025 | 54.52 | -53.14% |
| 2024 | 116.35 | 413.51% |
| 2023 | 22.66 | -49.84% |
| 2022 | 45.17 | 16.64% |
| 2021 | 38.73 | -47.52% |
| 2020 | 73.79 | 32.05% |
| 2019 | 55.89 | 34.74% |
| 2018 | 41.48 | -28.95% |
| 2017 | 58.37 | -35.18% |
| 2016 | 90.05 | 5.48% |
| 2015 | 85.38 | 63.88% |
| 2014 | 52.10 | -27.90% |
| 2013 | 72.26 | 92.73% |
| 2012 | 37.49 | -10.84% |
| 2011 | 42.05 | -32.77% |
| 2010 | 62.55 | -71.25% |
| 2009 | 217.57 | 0.00% |
Raportul P/E pentru companii similare sau concurenți
| Companie | P/E Ratio | Diferență P/E Ratio | Țara |
|---|---|---|---|
| 30.83 | -95.03% |
US
|
|
| -29.16 | -104.70% |
US
|
|
| -25.99 | -104.19% |
AU
|
|
| 22.43 | -96.39% |
BE
|
|
| 31.22 | -94.97% |
NL
|
Cum interpretezi un P/E ratio?
Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.
Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.
Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.